Citadel Advisors’s LeMaitre Vascular LMAT Stock Holding History

Citadel Advisors’s Portfolio LMAT Stock Details LMAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$371K	Buy	+3,400	New	+$324K	﹤0.01%	9979
2025 Q4	–	Sell	-2,500	Closed	-$219K	–	13475
2025 Q3	$219K	Buy	+2,500	New	+$223K	﹤0.01%	11077
2025 Q2	–	Sell	-300	Closed	-$25.2K	–	13960
2025 Q1	$25.2K	Sell	300 -3,300	-92%	-$307K	﹤0.01%	12968
2024 Q4	$332K	Sell	3,600 -1,600	-31%	-$154K	﹤0.01%	9446
2024 Q3	$483K	Buy	5,200 +1,600	+44%	+$139K	﹤0.01%	8333
2024 Q2	$296K	Sell	3,600 -500	-12%	-$36.7K	﹤0.01%	9164
2024 Q1	$272K	Sell	4,100 -1,300	-24%	-$80.2K	﹤0.01%	9681
2023 Q4	$307K	Sell	5,400 -2,900	-35%	-$152K	﹤0.01%	9115
2023 Q3	$452K	Buy	8,300 +7,900	+1,975%	+$468K	﹤0.01%	8273
2023 Q2	$26.9K	Buy	400 +300	+300%	+$18.3K	﹤0.01%	12465
2023 Q1	$5.15K	Buy	+100	New	+$4.86K	﹤0.01%	13889
2022 Q2	–	Sell	-10,400	Closed	-$483K	–	13576
2022 Q1	$483K	Buy	+10,400	New	+$465K	﹤0.01%	9482
2021 Q3	–	Sell	-5,800	Closed	-$354K	–	14291
2021 Q2	$354K	Buy	+5,800	New	+$308K	﹤0.01%	10863

Other funds holding LMAT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

GCM

Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Citadel Advisors's LMAT Position: Q1 2026 in Review

Citadel Advisors increased its LeMaitre Vascular (LMAT) stake by 546% in Q1 2026, buying an estimated $7.82M and bringing the position to 97,083 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3168.

Citadel Advisors first reported a position in LMAT in Q4 2015 and has held it in 37 quarters since. 339 funds tracked by Wall St. Rank hold LMAT as of Q1 2026.

Citadel Advisors held 97,083 shares of LeMaitre Vascular worth $10.6M as of Q1 2026.
Citadel Advisors bought 82,047 LeMaitre Vascular shares in Q1 2026, an estimated $7.82M.
LeMaitre Vascular made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3168 holding.
Citadel Advisors first reported a position in LeMaitre Vascular in Q4 2015 and has held it in 37 quarters since.
339 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.